跳至主要内容
临床试验/EUCTR2018-000741-39-FR
EUCTR2018-000741-39-FR进行中(未招募)1 期

EFFECT OF AZITHROMYCIN ON THE PROPORTION OF FAILURES OF SEVERE PERIODONTITIS NON-SURGICAL TREATMENTS : A RANDOMIZED, DOUBLE-BLIND VERSUS PLACEBO STUDY - AZITHROPARO

Hôpitaux Universitaires de Strasbourg0 个研究点目标入组 124 人开始时间: 2019年9月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
124

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Patient over 35 years of age
  • - Patient with severe chronic periodontitis (loss of attachment = 5mm) generalized (>30% sites) (AAP 1999 classification) and pockets > 5mm on at least 5% of sites
  • - Presence of bleeding on the catheter (= 30%)
  • - Patient with at least 15 teeth including 2 molars (excluding wisdom teeth)
  • - Patient benefiting from a social protection system
  • - Voluntary patient with informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 100
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 24

排除标准

  • - Patient with contraindications to treatment with azithromycin or its excipient: absolute contraindications are the history of allergy to macrolides or to one of the excipients used in this study, combination with ergot derivatives, cisapride, colchicine and severe liver failure (azithromycin being essentially eliminated by the bile ducts). Other contraindications are in patients at risk of cardiac arrhythmias (diagnosis of QT prolongation and/or concomitant treatments, electrolyte disorders (hypokalemia, hypomagnesia, cardiac arrhythmias, heart failure), severe renal failure, and some drug combinations (antivitamin K, statins)
  • - Patient with aggressive periodontitis (AAP 1999 classification)
  • - Patient smoking more than 10 cigarettes/day
  • - Patient at risk of type B infection (endocarditis) or requiring antibiotic prophylaxis,
  • - Patient who has received antibiotic treatment in the 6 months preceding the periodontal examination
  • - Patient who has received anti-inflammatory treatment in the month preceding the periodontal examination and/or anti-inflammatory treatment for more than 3 consecutive days in the 3 months preceding the periodontal examination
  • - Patient on or after drug treatment (cyclosporine and other anti-rejection, anti-epileptic, calcium channel blocker drugs) affecting periodontal status
  • - Patient with pathologies affecting the periodontal state and/or the systemic or local inflammatory response, such as diabetes, infectious or non-infectious stomatitis, inflammatory and autoimmune diseases, immunosuppression
  • - Patient with a prolonged oral hygiene disability (physical/psychic inability to brush teeth)
  • - Patient with a dilapidated oral condition (untreated cavities, unrestated teeth), oral infectious foci whose management requires antibiotic treatment within 6 months
  • - Patient who has had specialized periodontal treatment, curettage/surfacing, or periodontal surgery in the year preceding the examination.
  • - Pregnant woman (controlled by a negative urine beta-HCG test at inclusion) or during breastfeeding
  • - Patient with chronic infections that occur repeatedly (more than 3 times per year) and require antibiotics
  • - Patients who received oral antiseptic treatment in the month prior to the examination
  • - Patient with swallowing disorders
  • - Patient included in another intervention research protocol, or in periods of exclusion (participation in observational research is still possible)
  • - Patient under guardianship and safeguard of justice
  • - Patient with a high risk of bleeding and/or INR>4.
  • - Patient unable to cooperate or understand study and care instructions
  • - Patient under guardianship, curatorship or guardianship

研究者

发起方
Hôpitaux Universitaires de Strasbourg

相似试验